City
Epaper

Belgium vax candidate protects against Covid-19: Study

By IANS | Updated: December 2, 2020 13:45 IST

London, Dec 2 Belgium virologists have developed a vaccine candidate against Covid-19 based on the yellow fever vaccine, ...

Open in App

London, Dec 2 Belgium virologists have developed a vaccine candidate against Covid-19 based on the yellow fever vaccine, which as a result also works against yellow fever.

The study, published in the journal Nature, showed that the vaccine protects hamsters from infection with the SARS-CoV-2 coronavirus after a single dose. The vaccine is also effective in monkeys. The team is currently preparing for clinical trials.

To engineer their vaccine, tentatively named RegaVax, the team from Rega Institute for Medical Research in Belgium, inserted the genetic code of the SARS-CoV-2 spikes into the genetic code of the yellow fever vaccine.

They tested the vaccine in healthy hamsters and monkeys. Another group of the animals received a placebo.

"In some of the monkeys, we observed neutralising antibodies already seven days after vaccination. After 14 days, high titers of neutralizing antibodies were measured in all animals." the study authors wrote.

"This is very fast. Moreover, in the vaccinated animals, the virus was completely or nearly completely gone from their throats," they added.

RegaVax is a vector vaccine. It uses the genetic code of the yellow fever vaccine virus as a carrier (or vector) for the genetic code of the coronavirus spikes.

RegaVax works after one dose, unlike many of the front-runners in the race today, which require a repeat vaccination after one month.

"We expect that the vaccine will offer long-lasting immunity to Covid-19," the authors said.

"It could therefore be an ideal candidate for repeat vaccinations when immunity decreases in people who have received one of the first-generation vaccines," they wrote.

Finally, the vaccine can be stored at 2-8 degree Celsius, while some vaccines require a cold chain with temperatures down to -70 degree Celsius.

The team is now preparing for clinical trials next year and has joined forces with a specialised and accredited company that will produce the vaccine candidate for testing in humans.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

NationalCongress now spreading confusion over Aravalli: Rajasthan BJP

Other SportsGuardiola has significantly helped me refine my game, says Man City star Erling Haaland

InternationalCISF organises study programme for Nepal Armed Police Force officers

NationalDisproportionate assets case: K’taka Lokayukta raids multiple locations

InternationalUS Embassy, consulates in India to remain closed from December 24-26

Health Realted Stories

HealthPeople in Varanasi to get 24 'Smart Parks' with yoga, walking & gym facilities near their homes

HealthKerala's first skin bank becomes operational in Thiruvananthapuram

Health‘Multai to Multapi’: MP CM announces name change; foundation stone laid for new medical college

HealthGovt reaffirms commitment to integrate surveillance, strengthen labs to combat influenza

HealthExperts call for ramping up science and tech investment in India